We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Leica Biosystems develops and supplies cancer diagnostics devices and solutions in the areas of histology, digital pa... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

By LabMedica International staff writers
Posted on 25 Jan 2021
Print article
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).
DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for prognostic, predictive, and therapeutic implications.

MMR is a highly conserved process involving the four key genes mutL homologue 1 (MLH1), mutS homologue 2 (MSH2), mutS homologue 6 (MSH6), and postmeiotic segregation increased 2 (PMS2), which act to identify and repair mismatched base pairs that may arise during DNA replication. Recent studies have shown that patients with microsatellite instability-high (MSI-H) or mismatch repair–deficient (dMMR) advanced cancers can benefit from treatment with a immune checkpoint inhibitor.

Medical Scientists at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) identified surgical pathology cases of colorectal and endometrial carcinomas with known MMR/MSI status and matched effusions with available cell blocks (CBs). Cell block sections were evaluated for adequacy and stained with MMR IPOX (MSH2, MSH6, MLH1, and PMS2). Cytological effusion specimens were collected at the institution by using standard techniques, received fresh in the cytology laboratory, and processed within 48 hours and a cell block was prepared according to previously described techniques and a laboratory protocol.

Immunoperoxidase staining for MLH1, PMS2, MSH2, and MSH6 was performed on unstained CB sections with the Leica Bond III stainer (Leica Biosystems, Buffalo Grove, IL, USA). The team identified 748 cases with MMR/MSI testing on surgical specimens having matched effusions. Of these, 131 cases (17.5%) had an available CB and 53 were deemed adequate for MMR IPOX staining. MMR IPOX results between effusion CBs and surgical pathology specimens were concordant in 45 of 53 (85%), inconclusive in six of 53 (11%), and discordant in two of 53 (4%) cases.

The authors concluded that there was high concordance of MMR IPOX testing between cytological and surgical specimens, with no false-positive and only two false-negative CB results. Limited tumor cells, staining in cells indefinite as tumor, tumor staining heterogeneity, and lack of internal control staining were problematic in some cases. Their findings indicate that cytological effusion specimens may be suitable substrates for MMR IPOX biomarker testing; however, inconclusive cases need to be interpreted with caution. The study was published in the January 2021 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
The University of Texas MD Anderson Cancer Center
Leica Biosystems

Gold Supplier
Virus Transport and Preservation Medium – Inactivated
Virus Transport and Preservation Medium – Inactivated
Multi-Well Sample Loader
Gold Supplier
COVID-19 Antigen Test
Rapid COVID-19 Antigen Test
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more


view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.